Method of enhancing tgf-beta signalling
AssigneesAuxagen, Inc., Saint Louis University
InventorsJung San Huang, Shuan Shian Huang
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method of enhancing TGF-β signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-β signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-β signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.
Claims16
A method of enhancing TGF-beta signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-beta signaling.
A method of treating a condition characterized by decreased TGF-β signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.
A method of accelerating wound healing in a patient in need thereof comprising administering to the patient a therapeutically effective amount a clathrin-dependent endocytosis inhibitor.
A method of inhibiting carcinogenesis in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.
A method of treating atherosclerosis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of dynasore.
A pharmaceutical composition comprising a therapeutically effective amount of a clathrin-dependent endocytosis inhibitor, a therapeutically effective amount of statin and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.